SCHEMBL6385274

SCHEMBL6385274

Cc1ccccc1CCc1ccncc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 10/20 0.50
NOTUM Q6P988 1/20 0.49
HTT P42858 1/20 0.46
KDM6B O15054 5/20 0.43
TDP1 Q9NUW8 2/20 0.42
SIRT3 Q9NTG7 1/20 0.42
FOLH1 Q04609 1/20 0.42
ALDH1A1 P00352 2/20 0.42
SLC16A3 O15427 1/20 0.42
KDM4D Q6B0I6 3/20 0.41
KDM4A O75164 3/20 0.41
KDM4E B2RXH2 2/20 0.41
NR3C2 P08235 1/20 0.41
EGLN3 Q9H6Z9 1/20 0.41
GPR84 Q9NQS5 1/20 0.40
SGMS2 Q8NHU3 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6386775 0.83 TSHR (0.49) NOTUMALDH1A1KDM4ESGMS2MEN1
SCHEMBL10751618 0.83 KDM4C (0.56) KDM4CKDM6BTDP1ALDH1A1KDM4D
SCHEMBL9644380 0.82 FOLH1 (0.61) HTTFOLH1ALDH1A1SLC16A3KDM4E
SCHEMBL6390426 0.82 KDM4C (0.43) KDM4CKDM6BTDP1FOLH1ALDH1A1
SCHEMBL21983945 0.80 TAAR1 (0.50) NOTUMHTTALDH1A1KDM4ENR3C2
SCHEMBL258369 0.79 KDM4C (0.51) KDM4CKDM6BTDP1SIRT3ALDH1A1
SCHEMBL258224 0.78 KDM6B (0.59) KDM4CKDM6BTDP1ALDH1A1KDM4D
Hydrochloric Acid SCHEMBL5739434 0.78 KDM4C (0.50) KDM4CKDM6BTDP1SIRT3ALDH1A1
SCHEMBL9858541 0.77 KDM4C (0.47) KDM4CKDM6BTDP1SIRT3FOLH1
SCHEMBL123203 0.77 KDM4C (0.51) KDM4CKDM6BTDP1SIRT3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245503-A1 Therapeutic heterocycles ASTRAZENECA AB (SE) 2005-11-03 US disclosed
EP-1458684-A2 THERAPEUTIC HETEROCYCLES AstraZeneca AB (SE) 2004-09-22 EP disclosed
WO-2003051276-A2 THERAPEUTIC HETEROCYCLES ASTRAZENECA AB (SE) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245503-A1 Therapeutic heterocycles OPRK1, RECQL, OPRM1 KDM4C 1795/4885NOTUM 4701/4885HTT 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.